SEC Company Response from Armata Pharmaceuticals, Inc. (ARMP) (CIK 0000921114) (ARMP) — Dec 23, 2014
Armata Pharmaceuticals, Inc. (ARMP) (CIK 0000921114)
Date: Dec. 23, 2014 · CIK: 0000921114 · Accession: 0001144204-14-075769
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-193458
Letter
Re: AmpliPhi Biosciences Corporation
December 23, 2014
BY EDGAR
Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, DC 20549
Registration Statement on Form S-1, as amended
File No. 333-193458
Request for Acceleration of Effectiveness
Ladies and Gentlemen:
Pursuant to Rule 461 of the Securities Act of 1933, as amended, AmpliPhi Biosciences Corporation, a Washington corporation (the “Company”), hereby requests that the Securities and Exchange Commission (the “Commission”) take appropriate action to cause the above-referenced Registration Statement to become effective at 4:00 PM, New York City time, on December 29, 2014, or as soon thereafter as possible on such date. The Company also requests the Commission to specifically confirm such effective date and time to the Company in writing.
The Company hereby acknowledges that:
· Should the Commission or the staff of the Commission (the “Staff”), acting pursuant to delegated authority, declare the filing effective, it does not foreclose the Commission from taking any action with respect to the filing;
· The action of the Commission or the Staff, acting pursuant to delegated authority, in declaring the filing effective, does not relieve the Company from its full responsibility for the adequacy and accuracy of the disclosure in the filing; and
· The Company may not assert Staff comments and the declaration of effectiveness as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.
Should you have any questions or require any additional information with respect to this filing, please contact the undersigned at (804) 205-5069. Thank you for your assistance and cooperation.
Sincerely,
AMPLIPHI BIOSCIENCES CORPORATION
Show Raw Text
CORRESP
1
filename1.htm
December 23, 2014
BY EDGAR
Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, DC 20549
Re:
AmpliPhi Biosciences Corporation
Registration Statement on Form S-1, as amended
File No. 333-193458
Request for Acceleration of Effectiveness
Ladies and Gentlemen:
Pursuant to Rule 461 of the Securities
Act of 1933, as amended, AmpliPhi Biosciences Corporation, a Washington corporation (the “Company”), hereby
requests that the Securities and Exchange Commission (the “Commission”) take appropriate action to cause the
above-referenced Registration Statement to become effective at 4:00 PM, New York City time, on December 29, 2014, or as soon thereafter
as possible on such date. The Company also requests the Commission to specifically confirm such effective date and time to the
Company in writing.
The Company hereby acknowledges that:
· Should the Commission or the staff of the Commission (the “Staff”), acting pursuant
to delegated authority, declare the filing effective, it does not foreclose the Commission from taking any action with respect
to the filing;
· The action of the Commission or the Staff, acting pursuant to delegated authority, in declaring
the filing effective, does not relieve the Company from its full responsibility for the adequacy and accuracy of the disclosure
in the filing; and
· The Company may not assert Staff comments and the declaration of effectiveness as a defense in
any proceeding initiated by the Commission or any person under the federal securities laws of the United States.
Should you have any questions or require
any additional information with respect to this filing, please contact the undersigned at (804) 205-5069. Thank you for your assistance
and cooperation.
Sincerely,
AMPLIPHI BIOSCIENCES CORPORATION
/s/ David E. Bosher
David E. Bosher
Interim Chief Financial Officer
AmpliPhi Biosciences Corporation
cc: Stephen B. Thau, Esq., Morrison & Foerster LLP
US: 4870
Sadler Rd, Suite 300, Glen Allen, VA 23060
AU: Unit 7
27 Dale Street, Brookvale 2100 NSW